Showing 1 - 10 of 14
Rationalisierungsmaßnahmen sind bei steigenden Ausgaben in einem vor allem durch Umlagen finanzierten Gesundheitssystem wichtige Mittel zur Erreichung einer effizienten Produktion und Allokation der Ressourcen. In diesem Artikel werden verschiedene deutsche Regulierungsansätze zur Stärkung...
Persistent link: https://www.econbiz.de/10009633798
Persistent link: https://www.econbiz.de/10010252917
Persistent link: https://www.econbiz.de/10011541102
Persistent link: https://www.econbiz.de/10011306421
Persistent link: https://www.econbiz.de/10011798902
We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 700 antidiabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of...
Persistent link: https://www.econbiz.de/10010481411
We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 700 anti-diabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of...
Persistent link: https://www.econbiz.de/10010338113
We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 700 anti-diabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of...
Persistent link: https://www.econbiz.de/10010339071
Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to steer drug demand and to control expenses. For example, they introduce reference pricing or tiered co-payments to enhance drug substitution and competition. Since 2006, Germany...
Persistent link: https://www.econbiz.de/10009522774
This paper evaluates the impact of reference pricing on prices and co-payments in the (German) market for off-patent pharmaceuticals. We present a theoretical model with price-sensitive and loyal consumers that shows that a decrease in the reference price affects the consumers' co-payments in a...
Persistent link: https://www.econbiz.de/10010489291